Biotech

Latest Articles

Basilea credit ratings $268M BARDA funding for antifungals, prescription antibiotics

.Basilea Pharmaceutica's job establishing brand new antifungals has actually received a significant ...

Capricor sells Europe rights to late-stage DMD treatment for $35M

.Possessing currently gathered up the U.S. civil rights to Capricor Therapeutics' late-stage Duchenn...

FDA fragments adcomm for Applied's rare disease medication

.After pushing the choice date for Applied Therapeutics' metabolic ailment medication govorestat, th...

Novo inks $600M NanoVation offer to examine hereditary medications ex-liver

.Novo Nordisk is actually proceeding its own press into genetic medications, consenting to compensat...

Innovent hyperlinks cytokine to colon cancer responses

.Innovent Biologics has actually made the scenario that its own checkpoint inhibitor-cytokine blend ...

Merck, Daiichi ADC strikes target in phase 3 lung cancer research study

.A stage 3 trial of Daiichi Sankyo and Merck &amp Co.'s HER3-directed antibody-drug conjugate (ADC) ...

Rakovina strengthens AI center along with collab to choose cancer aim ats

.5 months after Rakovina Therapies rotated toward artificial intelligence, the cancer-focused biotec...

Ascendis' dwarfism drug favorites in phase 3, intimidates BioMarin

.Ascendis Pharma has actually become a prospective danger to BioMarin's Voxzogo, reporting phase 3 g...

Despite ph. 3 skip, Alkeus views pathway in advance for eye ailment asset

.Though Alkeus Pharmaceuticals' dental eye ailment resource fell short to substantially minimize geo...

Kairos goes social with $6M IPO to fund tests of cancer drug

.Along with a triad of biotechs hitting the Nasdaq on Friday, it was actually effortless to miss a s...

Vaccine as well as Keytruda combination effective in squamous cell carcinoma

.Immune checkpoint inhibitors are actually the superheroes of cancer cells treatment. Medications li...

Cue Biopharma queues up J&ampJ vet as CBO-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of significant leadership hirings, shootings as...

Regeneron's Opdualag opponent shows 57% action cost

.Regeneron is back with long-term follow-up for its LAG-3 prevention as well as PD-1 prevention comb...

AstraZeneca messages information on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early check out the efficiency of its own in-house antibo...

iTeos- GSK's TIGIT superstar shows relevant improvement

.After revealing a period 3 launch based upon good midstage end results, iTeos as well as GSK are ac...

More collective FDA can easily increase rare condition R&ampD: file

.The FDA must be extra available and also collaborative to let loose a rise in approvals of uncommon...

Zenas, MBX, Bicara scalp to Nasdaq in scorching day for biotech IPOs

.It is actually an abnormally hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX and Bi...

Atea's COVID antiviral fails to stop hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has actually stopped working one more COVID-19 test, but the biotec...

Neurocrine's proposal to save schizophrenia possibility fails

.Neurocrine Biosciences' mental illness program pivot has stopped working. The biotech was unable to...

Sanofi pays out $110M upfront for late-stage radioligand treatment

.Sanofi has actually made a late entrance to the radioligand event, paying one hundred million europ...